8-K Announcements
6Material company update
Apr 9, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Jan 7, 2026·SEC
FibroGen, Inc.(FGEN)Earnings, Financials & Key Ratios
FGEN•NASDAQ
$7.50
Price updated Jun 20, 2026
AboutFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Show more
- Revenue$30M-36.7%
- EBITDA-$148M+52.8%
- Net Income-$48M+83.3%
- EPS (Diluted)-0.48+83.6%
- Gross Margin47.47%-48.1%
- EBITDA Margin-498.71%+25.4%
- Operating Margin-507.8%+26.4%
- Net Margin-160.63%+73.6%
FGEN Price & Volume
FibroGen, Inc. (FGEN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Erosion Masks Deep Structural Impairment
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- FibroGen faces a precarious outlook as its core anemia franchise experiences severe commercial contraction, with revenue plummeting to $1.1M in 2025Q3.
- The company's reliance on non-operating items to report a $200.6M net profit obscures a fundamental inability to generate sustainable operating cash flow, which remained negative at -$1.8M in the same period.
- Investors should remain cautious given the rapid depletion of assets from $515.1M in 2023Q2 to $137.0M and the persistent negative equity position of -$17.0M.
Verdict Logic
the company's reliance on non-operating gains to mask a $1.8M operating cash burn and the erosion of total assets to $137.0M suggest significant long-term insolvency risks.
FGEN Growth Metrics
FibroGen, Inc. (FGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.24%
5 Years-35.07%
3 Years-49.88%
TTM-218.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM277.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM678.32%
Return on Capital
10 Years-44.09%
5 Years-73.3%
3 Years-97.28%
Last Year-104.79%
FGEN Recent Earnings
FibroGen, Inc. (FGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q4 2025Latest
Nov 10, 2025Metric
Actual
Est
EPS
$1.61+59.9%
$4.01
Rev
$1M-35.6%
$2M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$3.38-50.2%
$2.25
Rev
$1M-53.5%
$3M
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$4.00-633.3%
$0.75
Rev
$3M+37.0%
$2M
Q2 2025
Mar 17, 2025Metric
Actual
Est
EPS
$0.08+0.0%
$0.08
Rev
$123M-594.8%
$25M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 10, 2025 | $1.61vs $4.01+59.9% | $1Mvs $2M-35.6% |
| Q3 2025 | Aug 11, 2025 | $3.38vs $2.25-50.2% | $1Mvs $3M-53.5% |
| Q2 2025 | May 12, 2025 | $4.00vs $0.75-633.3% | $3Mvs $2M+37.0% |
| Q2 2025 | Mar 17, 2025 | $0.08vs $0.08+0.0% | $123Mvs $25M-594.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for FibroGen, Inc. (FGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.50 | $585M | -15.63 | -36.71% | -160.63% | — | 0.3% | |
| $1.36 | $364.83M | -65.38 | 47.46% | -8.83% | -62.72% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $112.84 | $24.46B | -17.60 | 66.73% | -144.44% | -130.11% | — |
Compare FGEN vs Peers
FibroGen, Inc. (FGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FGEN SEC Filings & Documents
FibroGen, Inc. (FGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when FGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FGEN Frequently Asked Questions
FibroGen, Inc. (FGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is FibroGen, Inc.'s revenue?
FibroGen, Inc. (FGEN) reported $-118.1M in revenue for fiscal year 2024. This represents a 279% decrease from $65.9M in 2012.
How fast is FibroGen, Inc. growing?
FibroGen, Inc. (FGEN) saw revenue decline by 36.7% over the past year.
Is FGEN profitable?
Yes, FibroGen, Inc. (FGEN) is profitable, generating $215.7M in net income for fiscal year 2024 (-160.6% net margin).
Dividend & Returns
Does FGEN pay dividends?
Yes, FibroGen, Inc. (FGEN) pays a dividend with a yield of 0.30%. This makes it attractive for income-focused investors.
What is FibroGen, Inc.'s free cash flow?
FibroGen, Inc. (FGEN) had negative free cash flow of $17.1M in fiscal year 2024, likely due to heavy capital investments.